Acute Myeloid Leukemia Treatment Market to Witness Modest Growth by 2020, According to a New Study on ASDReports

Wednesday 26 November 2014, Amsterdam

The value of the global Acute Myeloid Leukemia (AML) therapeutics market will increase moderately from $632.6 million in 2013 to $878.6 million by 2020, representing a Compound Annual Growth Rate (CAGR) of 4.8%, says the new report

The company’s latest report states that this growth, which will occur across eight major markets (the US, UK, Canada, Germany, France, Italy, Spain and Japan), is attributable to rising AML prevalence and the anticipated launches of five premium-priced drugs into a market dominated by generics.

Promising novel treatments, CPX-351, midostaurin, quizartinib, StemEx and treosulfan, have demonstrated encouraging efficacy and safety benefits in small patient cohorts in early clinical trials.

These drugs are expected to show similar positive results in later studies, resulting in their approval during the forecast period, following which they are expected to outcompete inferior drugs and increase treatment rates.

Katie Noon, Analyst for the new report, says: “The current developmental pipeline for AML has a strong number of drug candidates in both the late and early stages, especially for an orphan indication.

“While AML treatment is dominated by generic chemotherapeutic agents, which have been the treatment of choice for the past four decades, the pipeline dynamics now suggest a strong focus on targeted therapies. These are predominately small molecule inhibitors of serine threonine proteins kinases, immunological agents against tumor-associated antigens/genes, and antagonists against cell-surface receptors.”

Despite the active pipeline, the new report states that increasing stem cell transplant rates, combined with a lack of standardized treatment and high disease heterogeneity, could decrease AML prevalence, therefore hindering the positive effects of new drug approvals and AML drug market expansion by 2020.

Noon continues: “Significant developments in transplant methods and safety have made these procedures the most effective form of AML treatment across all patients.

“A rise in stem cell transplants will allow for long-term remissions and higher recovery rates, lowering both AML prevalence and the demand for pharmacological therapeutics,” the analyst concludes.